Skip to main content

IMGIP22070 / CL-SBP-101-04 / Dunne

Research Question:
Does the drug, SBP-101 effectively treat metastatic pancreatic cancer?

Basic Study Information

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.

Location: University of Rochester
Study Reference #: STUDY00007707

Lead Researcher (Principal Investigator)

Lead Researcher:  Richard Dunne

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search